Skip to main content

Table 1 Baseline characteristics

From: Impact of the obesity paradox on 28-day mortality in elderly patients critically ill with cardiogenic shock: a retrospective cohort study

Characteristic

Younger

 

Older

BMI < 30

N = 321

BMI ≥ 30

N = 250

P-value

BMI < 30

N = 865

BMI ≥ 30

N = 391

P-value

Age, years

56 (48, 61)

57 (48, 61)

0.652

79 (72, 86)

75 (70, 80)

 < 0.001

BMI, kg/m2

26 (23, 28)

35 (32, 39)

 < 0.001

25 (23, 27)

34 (32, 38)

 < 0.001

Sex

  

0.937

  

0.165

 Male

218 (67.91%)

169 (67.60%)

 

503 (58.15%)

211 (53.96%)

 

 Female

103 (32.09%)

81 (32.40%)

 

362 (41.85%)

180 (46.04%)

 

Comorbidities, %

      

 Hypertension

  

0.166

  

0.499

  No

245 (76.32%)

178 (71.20%)

 

628 (72.60%)

291 (74.42%)

 

  Yes

76 (23.68%)

72 (28.80%)

 

237 (27.40%)

100 (25.58%)

 

 Diabetes

  

0.007

  

 < 0.001

  No

240 (74.77%)

161 (64.40%)

 

546 (63.12%)

172 (43.99%)

 

  Yes

81 (25.23%)

89 (35.60%)

 

319 (36.88%)

219 (56.01%)

 

 AHF

  

0.006

  

0.081

  No

176 (54.83%)

108 (43.20%)

 

379 (43.82%)

192 (49.10%)

 

  Yes

145 (45.17%)

142 (56.80%)

 

486 (56.18%)

199 (50.90%)

 

 CKD

  

0.257

  

0.256

  No

205 (63.86%)

171 (68.40%)

 

551 (63.70%)

262 (67.01%)

 

  Yes

116 (36.14%)

79 (31.60%)

 

314 (36.30%)

129 (32.99%)

 

 ARF

  

0.246

  

0.922

  No

102 (31.78%)

91 (36.40%)

 

294 (33.99%)

134 (34.27%)

 

  Yes

219 (68.22%)

159 (63.60%)

 

571 (66.01%)

257 (65.73%)

 

 Severity index

      

  Sofa score

8.0 (5.0, 11.0)

7.0 (5.0, 10.0)

0.233

8.0 (5.0, 10.0)

7.0 (5.0, 10.0)

0.434

  Sirs score

3.0 (2.0, 3.0)

3.0 (2.0, 3.0)

0.708

3.0 (2.0, 3.0)

3.0 (2.0, 3.0)

0.408

 Inflammation indicator

      

  NLR

7.6 (6.2, 9.1)

7.4 (6.2, 8.8)

0.405

9.0 (7.0, 11.0)

9.0 (7.0, 11.0)

0.042

  CRP, mg/L

87 (74, 98)

90 (75,106)

0.022

92 (82,103)

99 (87,110)

 < 0.001

 Arterial blood gas

      

  PH

7.35 (7.27, 7.41)

7.36 (7.28, 7.42)

0.261

7.36 (7.28, 7.41)

7.37 (7.29, 7.42)

0.207

  PaCO2, mmHg

40 (36, 47)

42 (35, 48)

0.455

40 (35, 46)

40 (34, 47)

0.537

  PaO2, mmHg

89 (50, 169)

79 (42, 144)

0.085

88 (45, 175)

88 (42, 163)

0.781

  PaO2/FiO2

93 (56, 184)

84 (45,158)

0.065

90 (46, 177)

93 (46, 166)

0.859

  Lactate, mmol/L

2.40 (1.60, 3.80)

2.10 (1.43, 3.32)

0.017

2.30 (1.50, 3.70)

2.23 (1.50, 3.40)

0.301

Medicine use, %

      

 Eepinephrine use

  

0.676

  

0.433

  No

243 (75.70%)

193 (77.20%)

 

655 (75.72%)

288 (73.66%)

 

  Yes

78 (24.30%)

57 (22.80%)

 

210 (24.28%)

103 (26.34%)

 

 Norepinephrine use

  

0.939

  

0.075

  No

112 (34.89%)

88 (35.20%)

 

285 (32.95%)

149 (38.11%)

 

  Yes

209 (65.11%)

162 (64.80%)

 

580 (67.05%)

242 (61.89%)

 

 Dopamine use

  

0.080

  

0.048

  No

255 (79.44%)

183 (73.20%)

 

685 (79.19%)

290 (74.17%)

 

  Yes

66 (20.56%)

67 (26.80%)

 

180 (20.81%)

101 (25.83%)

 

 Furosemide use

  

0.659

  

0.788

  No

94 (29.28%)

69 (27.60%)

 

223 (25.78%)

98 (25.06%)

 

  Yes

227 (70.72%)

181 (72.40%)

 

642 (74.22%)

293 (74.94%)

 
  1. BMI Body mass index, AHF Acute heart failure, CKD Chronic kidney disease, ARF Acute renal failure, SOFA score Sepsis-related organ failure score, Sirs score Systemic inflammatory response syndrome score, CRP C-reactive protein, NLR neutrophil-to-lymphocyte ratio
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us